Sofia Gambigliani Zoccoli
Research Subjects
Sofia Gambigliani Zoccoli has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Antonino Farulla
Univ Modena & reggio emilia, Unit Minimally Invas & Robot Gynecol Surg, AOU Policlin Modena, Via Pozzo 71, I-41125 Modena, Italy
1 shared publication Antonio La Marca
1 shared publication- Antonio La Marca
University of Modena and Reggio Emilia
1 shared publication Carlo Alboni
1 shared publication- Carlo Alboni1 shared publication
Emma Bertucci
1 shared publication
Latest Publications
- Open Access
- 24 June 2026
- Published by Elsevier in SSRN Electronic Journal
The ultrasound-based #Enzian classification as a prognostic tool for fertility in women with endometriosis: a real-world cohort study
PurposeTo evaluate whether the ultrasound-based #Enzian classification provides prognostic information on fertility in women with endometriosis, and whether it can be used as a tool for individualized counselling regarding the likelihood of spontaneous and ART-assisted conception.MethodsWe conducted a retrospective cohort study at a tertiary referral center (2018-2023). From 723 women with endometriosis, 78 met the inclusion criteria: ultrasound-confirmed disease, active desire for pregnancy, and no hormonal therapy or surgery at baseline. Patients were followed for a median of 48 months (range 14-60). Clinical, sonographic, reproductive, and surgical data were collected. Associations between #Enzian compartments and pregnancy outcomes were analysed using Cox regression adjusted for male factor infertility.ResultsFifty-five of 78 women (70.5%) achieved pregnancy, with a live birth (LB) rate of 44.9% and a median time to pregnancy (TTP) of 24 months, confirming subfertility in this population. Among them, 36 conceived spontaneously and 19 through ART. During follow-up, 36 women (46.2%) underwent surgery after failed spontaneous attempts and worsening symptoms; 19 conceived postoperatively, resulting in 15 LB, with a median TTP of 36 months. Adenomyosis (F.A) and right tubo-ovarian adhesions (T.right) were significantly associated with reduced pregnancy rates (HR 0.27 and 0.74, respectively) and both negatively influenced ART success (HR for F.A 0.25). Compartment A (rectovaginal space and vagina) involvement was linked to significantly longer TTP (+10.2 months, p=0.020).ConclusionWomen with endometriosis are subfertile, with prolonged TTP and reduced LB rates. The ultrasound-based #Enzian classification provides compartment-specific prognostic information, supporting its role as a non-invasive tool to refine fertility counselling and guide clinical management.
- 24 June 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessThe ultrasound-based #Enzian classification as a prognostic tool for fertility in women with endometriosis: a real-world cohort study
PurposeTo evaluate whether the ultrasound-based #Enzian classification provides prognostic information on fertility in women with endometriosis, and whether it can be used as a tool for individualized counselling regarding the likelihood of spontaneous and ART-assisted conception.MethodsWe conducted a retrospective cohort study at a tertiary referral center (2018-2023). From 723 women with endometriosis, 78 met the inclusion criteria: ultrasound-confirmed disease, active desire for pregnancy, and no hormonal therapy or surgery at baseline. Patients were followed for a median of 48 months (range 14-60). Clinical, sonographic, reproductive, and surgical data were collected. Associations between #Enzian compartments and pregnancy outcomes were analysed using Cox regression adjusted for male factor infertility.ResultsFifty-five of 78 women (70.5%) achieved pregnancy, with a live birth (LB) rate of 44.9% and a median time to pregnancy (TTP) of 24 months, confirming subfertility in this population. Among them, 36 conceived spontaneously and 19 through ART. During follow-up, 36 women (46.2%) underwent surgery after failed spontaneous attempts and worsening symptoms; 19 conceived postoperatively, resulting in 15 LB, with a median TTP of 36 months. Adenomyosis (F.A) and right tubo-ovarian adhesions (T.right) were significantly associated with reduced pregnancy rates (HR 0.27 and 0.74, respectively) and both negatively influenced ART success (HR for F.A 0.25). Compartment A (rectovaginal space and vagina) involvement was linked to significantly longer TTP (+10.2 months, p=0.020).ConclusionWomen with endometriosis are subfertile, with prolonged TTP and reduced LB rates. The ultrasound-based #Enzian classification provides compartment-specific prognostic information, supporting its role as a non-invasive tool to refine fertility counselling and guide clinical management.
- 11 March 2026
- Published by S. Karger AG in Gynecologic and Obstetric Investigation
- p. 1-7
The #Enzian Classification as a Predictor of Hormonal Therapy Response in Endometriosis-Associated Pain: A Retrospective Cohort Study in a Referral Center
Objectives: The objective of this study was to evaluate whether ultrasound-based #Enzian classification predicts pain profiles and response to hormonal therapy in patients with endometriosis. Endometriosis is a chronic inflammatory disease affecting 10% of reproductive-age women, often causing debilitating pelvic pain. Although #Enzian is validated for surgical planning, its predictive role in medical therapy remains unexplored. Design: A retrospective cohort study, including 89 premenopausal patients referred between 2018 and 2023, was conducted. Hormonal therapies included progestin-only pills (dienogest – POP-D or other progestins – POP-O), combined estrogen-progestin pills (dienogest – EP-D or other EP-O), or norethisterone acetate. Pain was assessed via a 0–10 VAS at baseline, ≥3 months, and ≥6 months. Participants/Materials, Setting, Methods: Patients had ultrasound-confirmed endometriosis and were hormone therapy-naïve for ≥6 months. Baseline evaluation included demographic data, reproductive history, prior surgeries, and six pain domains. #Enzian classification mapped lesion location and size (A: rectovaginal/vagina; B: uterosacral/parametria; C: rectum; FA: adenomyosis; FB: bladder; FU: ureter; FI: intestine above rectum; FO: extra pelvic; O: ovary; P: peritoneum; T: fallopian tubes/adhesions). Linear regression and linear mixed-effects models assessed associations between #Enzian compartments and pain trajectories. Results: Dysmenorrhea occurred in 86.5%, and dyspareunia occurred in 56.2%. Ovarian endometriomas (O) were present in 76.4%, deep infiltrating endometriosis (A, B, C) in 51.7%, and adenomyosis (FA) in 66.3%. POP-D was most effective in reducing ovulatory pain in ovarian (O), uterosacral/parametria (B), rectal (C), and tubal/adhesion (T) involvement, while EP-D was superior for dyspareunia in T. Chronic pelvic pain (CPP) remained refractory. Higher total #Enzian scores correlated with reduced therapy efficacy. Limitations: Retrospective design, single-center, small sample, use of aggregated pain scores, and incomplete follow-up may limit generalizability. Conclusion: Ultrasound-based #Enzian classification correlates with lesion distribution and predicts hormonal therapy efficacy. POP-D therapy is superior at lower #Enzian scores; CPP remains challenging. Findings support individualized medical management and warrant prospective validation including multidimensional pain and quality-of-life assessments.
- 11 March 2026
- Published by S. Karger AG in Gynecologic and Obstetric Investigation
- p. 1-7
The #Enzian Classification as a Predictor of Hormonal Therapy Response in Endometriosis-Associated Pain: A Retrospective Cohort Study in a Referral Center
Objectives: The objective of this study was to evaluate whether ultrasound-based #Enzian classification predicts pain profiles and response to hormonal therapy in patients with endometriosis. Endometriosis is a chronic inflammatory disease affecting 10% of reproductive-age women, often causing debilitating pelvic pain. Although #Enzian is validated for surgical planning, its predictive role in medical therapy remains unexplored. Design: A retrospective cohort study, including 89 premenopausal patients referred between 2018 and 2023, was conducted. Hormonal therapies included progestin-only pills (dienogest – POP-D or other progestins – POP-O), combined estrogen-progestin pills (dienogest – EP-D or other EP-O), or norethisterone acetate. Pain was assessed via a 0–10 VAS at baseline, ≥3 months, and ≥6 months. Participants/Materials, Setting, Methods: Patients had ultrasound-confirmed endometriosis and were hormone therapy-naïve for ≥6 months. Baseline evaluation included demographic data, reproductive history, prior surgeries, and six pain domains. #Enzian classification mapped lesion location and size (A: rectovaginal/vagina; B: uterosacral/parametria; C: rectum; FA: adenomyosis; FB: bladder; FU: ureter; FI: intestine above rectum; FO: extra pelvic; O: ovary; P: peritoneum; T: fallopian tubes/adhesions). Linear regression and linear mixed-effects models assessed associations between #Enzian compartments and pain trajectories. Results: Dysmenorrhea occurred in 86.5%, and dyspareunia occurred in 56.2%. Ovarian endometriomas (O) were present in 76.4%, deep infiltrating endometriosis (A, B, C) in 51.7%, and adenomyosis (FA) in 66.3%. POP-D was most effective in reducing ovulatory pain in ovarian (O), uterosacral/parametria (B), rectal (C), and tubal/adhesion (T) involvement, while EP-D was superior for dyspareunia in T. Chronic pelvic pain (CPP) remained refractory. Higher total #Enzian scores correlated with reduced therapy efficacy. Limitations: Retrospective design, single-center, small sample, use of aggregated pain scores, and incomplete follow-up may limit generalizability. Conclusion: Ultrasound-based #Enzian classification correlates with lesion distribution and predicts hormonal therapy efficacy. POP-D therapy is superior at lower #Enzian scores; CPP remains challenging. Findings support individualized medical management and warrant prospective validation including multidimensional pain and quality-of-life assessments.